GoodRx Holdings (GDRX) Price to Sales (2020 - 2026)

GoodRx Holdings has disclosed Price to Sales across 7 years of filings, most recently posting 4.89 for Q2 2026.

• In Q2 2026, Price to Sales fell 43.5% year-over-year to 4.89; the TTM figure through Jun 2026 stood at 1.25 (down 43.2% YoY), while the FY2025 annual figure was 1.16, down 48.37% from the prior year.
• Price to Sales came in at 4.89 for Q2 2026 at GoodRx Holdings, up from 3.41 in the prior quarter.
• In the past five years, Price to Sales ranged from a high of 37.66 in Q1 2022 to a low of 3.41 in Q1 2026.
• Average Price to Sales over 5 years is 11.57, with a median of 10.8 recorded in 2022.
• Year-over-year, Price to Sales tumbled 88.22% in 2022 and surged 33.62% in 2023.
• Over 5 years, Price to Sales stood at 10.05 in 2022, then jumped by 33.62% to 13.43 in 2023, then slumped by 33.24% to 8.96 in 2024, then plunged by 47.07% to 4.74 in 2025, then advanced by 3.01% to 4.89 in 2026.
• Per Business Quant data, the three most recent Price to Sales figures were 4.89 in Q2 2026, 3.41 in Q1 2026, and 4.74 in Q4 2025.